Clinical trials: Organ Transplant Recipients
HIV Positive, Organ Transplant Recipient
Transplantation and the Use of Raltegravir in HIV-Infected Patients
Raltegravir (RAL) is a preferred option for initial antiretroviral therapy in the most recent HIV Treatment Guidelines and is emerging as a popular choice for use in the specialized population of HIV-infected patients being…
- Conditions
- HIV Positive, Organ Transplant Recipient, Active Wait Listing for Organ Transplant
- Trial name
- NCT01793467
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Duke University
Influenza (Pandemic), Avian Influenza
Pandemic Influenza Vaccine in Organ Transplantation (PIVOT Trial)
Influenza is an important pathogen in transplant recipients. The current widespread outbreak of highly pathogenic H5N1 avian influenza (HPAI) in livestock, and the occurrence of several human cases of infection suggest that the…
- Conditions
- Influenza (Pandemic), Avian Influenza, Vaccination
- Trial name
- PIVOT (NCT07240558)
- Testing
- H5N1 vaccine (Arepanrix, GSK)
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- University Health Network, Toronto
Renal Transplantation
Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients
This study will evaluate the safety and efficacy of FTY720 versus mycophenolate mofetil (MMF, Roche brand) combined with cyclosporine and corticosteroids in patients receiving a kidney transplant.
- Trial name
- NCT00239863
- Testing
- FTY720
- Volunteers
- 684 people
- Sponsor
- Novartis Pharmaceuticals
Cytomegalovirus (CMV) Infection
CytoGam for CMV Infection or Disease in Solid Organ Transplant Recipients
Cytomegalovirus (CMV) is a significant opportunistic pathogen and a major cause of morbidity and mortality in solid organ transplant recipients.
- Trial name
- NCT07009548
- Testing
- Cytogam
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Fernanda P Silveira, MD, MS
Actinic Keratosis, Warts
Photodynamic Therapy (PDT) With Metvix® 160 Milligrams/Gram Cream in Organ Transplant Participants With Non-melanoma Skin Cancer
Participants on immunosuppressive therapy, e.g., organ recipients, had higher occurrence of AK (Actinic Keratosis) than the untreated population.
- Conditions
- Actinic Keratosis, Warts, Basal Cell Carcinoma, Bowens Disease
- Trial name
- NCT00472459
- Testing
- Photodynamic therapy with Metvix 160 mg/g cream
- Where
- 11 sites in Denmark, Germany and 3 more
- Volunteers
- 82 people
- Sponsor
- Galderma R&D
Kidney Transplant; Complications
Solid Organ Transplant SHINGRIX
This study will assess the immune responses to the recombinant, AS01-adjuvanted varicella zoster virus subunit (HZ/su) vaccine or SHINGRIX in immunosuppressed patients, particularly those who have received a renal transplant, and…
- Trial name
- NCT03993717
- Testing
- SHINGRIX
- Where
- 4 sites in United States
- Volunteers
- 2 people
- Sponsor
- Emory University
Graft-Versus-Host Disease
Tissue Repair in Stem Cell Transplant Recipients
Primary Objective: 1. To determine whether rhG-CSF treatment will increase the frequency of donor-derived cells contributing to repair of damaged epithelial/endothelial or solid organ-specific tissue caused by graft-versus-host…
- Trial name
- NCT00501228
- Testing
- Filgrastim
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- M.D. Anderson Cancer Center
Kidney Injury, Kidney Failure
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure.
- Conditions
- Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute
- Trial name
- STAART (NCT05747053)
- Testing
- AlloSure, PAXGene
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- George Washington University
Malignant Diseases, Non-malignant Diseases
CD34+ Cell Enriched and T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Mismatched Related Donors or Borderline Organ Function
The purpose of this protocol is to provide access to the CliniMACS® System to hematopoietic cell transplant (HSCT) patients who do not have a matched related donor.
- Trial name
- NCT02162511
- Testing
- CliniMACS CD34+ cell enrichment and T-cell depletion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rajni Agarwal
Kidney Transplantation, Liver Transplantation
Quality of Life in Pediatric Transplant Recipients
Adherence to medical regimens refers to what degree a patient chooses to follow the advice given by his/her healthcare provider.
- Conditions
- Kidney Transplantation, Liver Transplantation, Heart Transplantation, Lung Transplantation
- Trial name
- NCT00209196
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Emory University
HIV, Awaiting Organ Transplant
HIV-to-HIV Transplant at MGH
HIV-infected (HIV+) individuals who agree to accept and receive a solid organ transplant from an HIV+ deceased donor will be followed to determine the safety and efficacy of this practice.
- Trial name
- NCT02750397
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Massachusetts General Hospital
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
The purpose of this study was to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor.
- Trial name
- NCT01974206
- Testing
- ASP0113
- Where
- 53 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Organ Donor, Brain Death
Therapeutic Hypothermia in "Expanded Criteria" Brain-dead Donors and Kidney-graft Function
Each year, only one third of patients registered on the waiting list receive a kidney transplant. Numerous paths are being explored with the aim of reversing this shortage.
- Conditions
- Organ Donor, Brain Death, Kidney Transplant; Complications, Critical Illness
- Trial name
- HYPOREME (NCT03098706)
- Testing
- Procedure control: normothermia, Procedure active
- Where
- 54 sites in France
- Volunteers
- 532 people
- Sponsor
- Nantes University Hospital
Immunization; Infection, Transplantation Infection
High vs. Standard Dose Influenza Vaccine in Adult SOT Recipients
The influenza virus is a significant cause of morbidity in adult solid organ transplant (SOT) recipients. However, these individuals show a suboptimal response to vaccines including the standard-dose (SD) inactivated influenza…
- Conditions
- Immunization; Infection, Transplantation Infection, Influenza, Solid Organ Transplant
- Trial name
- NCT04613206
- Testing
- High Dose Quadrivalent Inactivated Influenza Vaccine, Standard Dose Quadrivalent Inactivated Influenza Vaccine
- Where
- United States
- Volunteers
- 396 people
- Sponsor
- Vanderbilt University Medical Center
Cytomegalovirus Infections
Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ…
- Trial name
- ReCySOHT (NCT05234723)
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Infection in Solid Organ Transplant Recipients
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Valganciclovir is extensively used for cytomegalovirus (CMV) infection treatment and prophylaxis after solid organ transplantation (SOT). VGC dosing is problematic in children.
- Trial name
- NCT02503982
- Testing
- prophylactic Valganciclovir
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- Rabin Medical Center
Kidney Transplant, Kidney Transplant Recipient
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of…
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Trial name
- NCT00307125
- Testing
- Rituximab plus immunosuppression
- Where
- 17 sites in United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Advanced Cutaneous Squamous Cell Carcinoma
Study of Ruxolitinib in Solid Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
In this open-label, multicenter, Phase II study, the investigators propose to evaluate the efficacy of ruxolitinib, an orally administered inhibitor of JAK1/2, in solid organ transplant recipients with advanced cSCC.
- Trial name
- NCT04807777
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Columbia University
Postoperative Complications
Hyperinsulinemic Normoglycemic Clamp for Pancreas and Simultaneous Pancreas/Kidney Transplant Recipients
This study proposes a simple and safe way of lowering this complicate rate, while improving graft recovering and protecting the graft as it recovers from the transplant.
- Trial name
- NCT01001273
- Testing
- Hyperinsulinemic Normoglycemic Clamp
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Hepatitis B Virus (HBV), Lung Transplant Recipient
Combined Light, ExVivo, and Antivirals for Recipients of Lungs From HBV Donors
The aim of the study is to show that transplantation of lungs from Hepatitis B-infected donors is safe when using EVLP with UV light inactivation plus antivirals
- Trial name
- CLEAR-HBV (NCT07189377)
- Testing
- Entecavir, HBIG, EVLP UV Light Treatment
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto